Requirements of circulatory support during liver transplantation: are patients with familial amyloidosis different from other patients?
Viana
J S
JS
Department of Transplantation and Department of Anaesthesiology, University Hospitals of Coimbra, Coimbra, Portugal. jvviana@huc.min-saude.pt
Bento
C
C
Vieira
H
H
Neves
S
S
Seco
C
C
Perdigoto
R
R
Craveiro
A L
AL
Furtado
L
L
D000328:Adult; D017772:Amyloid Neuropathies / Q000601:surgery*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004280:Dobutamine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007430:Intraoperative Care; D008102:Liver Circulation; D016031:Liver Transplantation / Q000379:methods* / Q000502:physiology; D008297:Male; D010656:Phenylephrine / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D010656:Phenylephrine; D004280:Dobutamine